S&W Seed Company enters alfalfa seed development agreement with Generic Genetics

S&W Seed Company today announced it has entered into an agreement with Generic Genetics, which is led by renowned biotech trait developer David Stalker, to develop novel alfalfa seed varieties containing select biotechnology traits. As a number of unique technologies come off patent in the coming years, S&W will look to leverage Generic Genetics' knowledge of the patent landscape and scientific expertise to create varieties specific to S&W, utilizing current transgenic traits coupled with other trait technologies proprietary to Generic Genetics.

Dr. Stalker was one of the early pioneers in agricultural biotechnology, having worked for Calgene, Monsanto, Scotts Miracle-Gro, and Advanta, and has a unique background in understanding patent protection strategies. During his career, he has been instrumental in the introduction of transgenic traits in soybean, canola and cotton. Through Generic Genetics, Dr. Stalker is focused in bringing certain patented technologies that are on the cusp of going off-patent to the market.

Mark Grewal, chief executive officer of S&W Seed Company commented, "As the agricultural biotech industry reaches its silver anniversary, many patents are on the verge of expiration. S&W and Generic Genetics will be working together in an effort to leverage these opportunities for the alfalfa seed industry, utilizing a combination of unique technologies. Dave Stalker is one of the early pioneers within the ag-biotech industry and brings a tremendous depth of knowledge in terms of intellectual property and trait development. We believe that today's announcement is yet another example of S&W's commitment to develop varieties and traits to meet market demand."